SARS-CoV-2 Seroprevalence among Health Care Workers-A Voluntary Screening Study in a Regional Medical Center in Southern Germany.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
08 04 2021
Historique:
received: 04 03 2021
revised: 30 03 2021
accepted: 07 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 6 5 2021
Statut: epublish

Résumé

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is associated with a potentially severe clinical manifestation, coronavirus disease 2019 (COVID-19), and currently poses a worldwide challenge. Health care workers (HCWs) are at the forefront of any health care system and thus especially at risk for SARS-CoV-2 infection due to their potentially frequent and close contact with patients suffering from COVID-19. Serum samples from 198 HCWs with direct patient contact of a regional medical center and several outpatient facilities were collected during the early phase of the pandemic (April 2020) and tested for SARS-CoV-2-specific antibodies. Commercially available IgA- and IgG-specific ELISAs were used as screening technique, followed by an in-house neutralization assay for confirmation. Neutralizing SARS-CoV-2-specific antibodies were detected in seven of 198 (3.5%) tested HCWs. There was no significant difference in seroprevalence between the regional medical center (3.4%) and the outpatient institution (5%). The overall seroprevalence of neutralizing SARS-CoV-2-specific antibodies in HCWs in both a large regional medical center and a small outpatient institution was low (3.5%) at the beginning of April 2020. The findings may indicate that the timely implemented preventive measures (strict hygiene protocols, personal protective equipment) were effective to protect from transmission of an airborne virus when only limited information on the pathogen was available.

Identifiants

pubmed: 33917840
pii: ijerph18083910
doi: 10.3390/ijerph18083910
pmc: PMC8068211
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Commun. 2020 Oct 8;11(1):5064
pubmed: 33033249
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347204
JAMA. 2020 Jun 9;323(22):2245-2246
pubmed: 32391855
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Emerg Infect Dis. 2020 Jul;26(7):1470-1477
pubmed: 32255761
J Pathol. 2006 Jan;208(2):270-82
pubmed: 16362985
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Lancet Infect Dis. 2020 Dec;20(12):1401-1408
pubmed: 32758438
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Euro Surveill. 2020 May;25(18):
pubmed: 32400364
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Immunity. 2020 Jul 14;53(1):98-105.e5
pubmed: 32561270
N Engl J Med. 2020 May 14;382(20):1957-1958
pubmed: 32243118

Auteurs

Katharina Müller (K)

Bundeswehr Institute of Microbiology, 80937 Munich, Germany.
German Centre for Infection Research (DZIF), Partner Site Munich, 80937 Munich, Germany.

Philipp Girl (P)

Bundeswehr Institute of Microbiology, 80937 Munich, Germany.
German Centre for Infection Research (DZIF), Partner Site Munich, 80937 Munich, Germany.

Michaela Ruhnke (M)

Praxis Dr. J. Borde, Gesundheitszentrum Oberkirch, 77704 Oberkirch, Germany.

Mareike Spranger (M)

Praxis Dr. J. Borde, Gesundheitszentrum Oberkirch, 77704 Oberkirch, Germany.

Klaus Kaier (K)

Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, 79098 Freiburg, Germany.

Heiner von Buttlar (H)

Bundeswehr Institute of Microbiology, 80937 Munich, Germany.
German Centre for Infection Research (DZIF), Partner Site Munich, 80937 Munich, Germany.

Gerhard Dobler (G)

Bundeswehr Institute of Microbiology, 80937 Munich, Germany.
German Centre for Infection Research (DZIF), Partner Site Munich, 80937 Munich, Germany.

Johannes P Borde (JP)

Praxis Dr. J. Borde, Gesundheitszentrum Oberkirch, 77704 Oberkirch, Germany.
Department of Medicine II, Division of Infectious Diseases, Faculty of Medicine and Medical Center, University of Freiburg, 79098 Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH